Trial Profile
An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MUNIN
- Sponsors GlaxoSmithKline; GSK
- 26 Mar 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
- 05 Nov 2012 Follow-up results will be presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition according to a Genmab media release.